Breast Cancers with HER2 and CEP17 "Co-Amplification" by FISH: Pathologic Features and Clinical Outcomes

被引：0
|
作者：
Ballard, Morgan
Troxell, Megan
Jensen, Kristin
Allison, Kimberly H.
机构：
[1] Stanford Univ, Med Ctr, Stanford, CA 94305 USA
[2] Palo Alto VA Healthcare, Palo Alto, VA USA
来源：
LABORATORY INVESTIGATION | 2017年 / 97卷
关键词：
D O I：
暂无
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
112
引用
收藏
页码：31A / 31A
页数：1
相关论文
共 50 条
  • [31] Prevalence of polysomy 17 by OncoScan in Fluorescence In Situ Hybridization (FISH) HER2 Gene amplification by HER2 gene copy number of > 6.0 with HER2/CEP17 ratio of < 2.0 in breast cancer
    Apple, Sophia
    Murata-Collins, Joyce
    LABORATORY INVESTIGATION, 2018, 98 : 45 - 45
  • [32] High HER2 signals and HER2/CEP17 ratio tumours achieve better responses in breast cancer
    Exposito Afonso, I. J.
    del Pino Sedeno, T.
    Gonzalez Villa, I.
    Loro Ferrer, J. F.
    Cabrera Galvan, J. J.
    VIRCHOWS ARCHIV, 2020, 477 : S45 - S46
  • [33] Co-Amplification of Chromosome 17 Genes Impacts HER2 Scoring
    Badve, Sunil
    Gokmen-Polar, Yesim
    LABORATORY INVESTIGATION, 2016, 96 : 31A - 31A
  • [34] Co-Amplification of Chromosome 17 Genes Impacts HER2 Scoring
    Badve, Sunil
    Gokmen-Polar, Yesim
    MODERN PATHOLOGY, 2016, 29 : 31A - 31A
  • [35] Using the HER2/CEP17 FISH Ratio to Predict Pathologic Complete Response Following Neoadjuvant Anti-HER2 Doublet Therapy in HER2+Breast Cancer
    Lander, Eric M.
    Rappazzo, Katherine C.
    Huang, Li-Ching
    Hu, Jiun-Ruey
    Chen, Heidi
    Shyr, Yu
    Abramson, Vandana G.
    ONCOLOGIST, 2023, 28 (02): : 123 - 130
  • [36] HER2 positive (HER2/CEP17 ratio≥2.0) invasive mammary carcinomas with average <4.0 HER2 and <2.0 CEP17 signals/cell: Clinicopathologic features, correlation with HER2 immunohistochemistry and response to neoadjuvant chemotherapy
    Livasy, Chad A.
    Limentani, Kimberly
    Calhoun, Benjamin C.
    Limentani, Steven
    CANCER RESEARCH, 2015, 75
  • [37] Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer
    Varga, Zsuzsanna
    Tubbs, Raymond R.
    Wang, Zhen
    Sun, Yang
    Noske, Aurelia
    Kradolfer, Doris
    Bosshard, Giovanna
    Jochum, Wolfram
    Moch, Holger
    Oehlschlegel, Christian
    BREAST CANCER RESEARCH AND TREATMENT, 2012, 132 (03) : 925 - 935
  • [38] Co-amplification of the HER2 gene and chromosome 17 centromere: a potential diagnostic pitfall in HER2 testing in breast cancer
    Zsuzsanna Varga
    Raymond R. Tubbs
    Zhen Wang
    Yang Sun
    Aurelia Noske
    Doris Kradolfer
    Giovanna Bosshard
    Wolfram Jochum
    Holger Moch
    Christian Öhlschlegel
    Breast Cancer Research and Treatment, 2012, 132 : 925 - 935
  • [39] Clinical and Pathologic Features Associated with Invasive Breast Carcinoma with 2018 ASCO/CAP Group ISH 2 Results (HER2/CEP17 ratio ≥2.0 and Average HER2 Copy Number of <4.0)
    Hoda, Raza
    McIntire, Patrick
    Komforti, Miglena
    Downs-Kelly, Erinn
    MODERN PATHOLOGY, 2021, 34 (SUPPL 2) : 111 - 113
  • [40] Clinical and Pathologic Features Associated with Invasive Breast Carcinoma with 2018 ASCO/CAP Group ISH 2 Results (HER2/CEP17 ratio ≥2.0 and Average HER2 Copy Number of <4.0)
    Hoda, Raza
    McIntire, Patrick
    Komforti, Miglena
    Downs-Kelly, Erinn
    LABORATORY INVESTIGATION, 2021, 101 (SUPPL 1) : 111 - 113
12345